Search

Your search keyword '"Shimatsu, Akira"' showing total 283 results

Search Constraints

Start Over You searched for: Author "Shimatsu, Akira" Remove constraint Author: "Shimatsu, Akira" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
283 results on '"Shimatsu, Akira"'

Search Results

3. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis

4. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase

10. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial

11. THU032 Osilodrostat Is Effective And Well Tolerated In Patients Of Asian And Non-Asian Origin With Cushing's Disease: A Pooled Analysis From LINC 3 And LINC 4

23. The oral disposition index calculated from a meal tolerance test is a crucial indicator for evaluating differential normalization of postprandial glucose and triglyceride excursions in morbidly obese patients after laparoscopic sleeve gastrectomy

27. Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension

29. Abstract 13751: Vascular Endothelial Growth Factor-C Levels and Cardiovascular and All-cause Mortality in Patients With Suspected Coronary Artery Disease: From the ANOX Study

35. Abstract #1183056: Osilodrostat Therapy Improves Physical Features Associated with Hypercortisolism in Patients with Cushing’s Disease: Findings from the Phase III LINC 3 study

39. Effects of a new 75 g glucose- and high fat-containing cookie meal test on postprandial glucose and triglyceride excursions in morbidly obese patients

43. Rabphilin-3A as a Targeted Autoantigen in Lymphocytic Infundibulo-neurohypophysitis

44. Osilodrostat is an effective and well-tolerated treatment option for patients with Cushing’s disease (CD): Final results from the LINC3 study

45. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement

46. Abstract #1040637: Effect of Osilodrostat on Clinical signs, Physical Features and Health-related Quality of Life (HRQoL) by Degree of mUFC Control in Patients with Cushing’s Disease (CD): Results from the LINC3 Study

47. Durability of response and gender-based analysis from the LINC3 trial of osilodrostat in the treatment in cushing’s disease

48. Successful management of a patient with active Cushing‍’‍s disease complicated with coronavirus disease 2019 (COVID-19) pneumonia

50. Successful management of a patient with active Cushing’s disease complicated with coronavirus disease 2019 (COVID-19) pneumonia

Catalog

Books, media, physical & digital resources